摘要
Gemcitabine and carboplatin each have demonstrated effectiveness without increased neurotoxicity in pretreated patients with ovarian cancer. We evaluated the efficacy and safety of gemcitabine plus carboplatin in patients with recurrent ovarian cancer in a multicenter phase II study. Women with histologically proven measurable or evaluable epithelial ovarian cancer (any FIGO) who relapsed ≥ 6 months after discontinuation of firstline, platinum- containing therapy received gemcitabine 1000 mg/m2 on days 1 and 8 and carboplatin AUC 4 on day 1 (after gemcitabine) every 21 days for up to six cycles. Of the 40 enrolled/evaluable patients, 6 (15% ) had complete response and 19 (47.5% ) had partial response (PR), including one patient with PR in nonmeasurable disease (PRNM), for an overall response rate of 62.5% (95% CI, 45.8- 77.3% ). The median duration of response was 7.8 months (95% CI, 6.7- 10.0), the median time to progressive disease was 9.6 months (95% CI, 8.5- 11.0), and the median time to treatment failure was 9.3 months (95% CI, 8.2- 10.4). The main grade 3/4 toxicities were neutropenia (78% of patients), leukopenia (30% ), thrombocytopenia (18% ), and anemia (15% ); no grade 4 nonhematologic toxicities occurred, and grade 3 nonhematologic toxicities were mild. The combination of gemcitabine and carboplatin is active and feasible in platinum- sensitive patients with recurrent ovarian cancer. This regimen is undergoing further evaluation in a large phase III trial.
Gemcitabine and carboplatin each have demonstrated effectiveness without increased neurotoxicity in pretreated patients with ovarian cancer. We evaluated the efficacy and safety of gemcitabine plus carboplatin in patients with recurrent ovarian cancer in a multicenter phase II study. Women with histologically proven measurable or evaluable epithelial ovarian cancer (any FIGO) who relapsed ≥ 6 months after discontinuation of firstline, platinum- containing therapy received gemcitabine 1000 mg/m2 on days 1 and 8 and carboplatin AUC 4 on day 1 (after gemcitabine) every 21 days for up to six cycles. Of the 40 enrolled/evaluable patients, 6 (15% ) had complete response and 19 (47.5% ) had partial response (PR), including one patient with PR in nonmeasurable disease (PRNM), for an overall response rate of 62.5% (95% CI, 45.8- 77.3% ). The median duration of response was 7.8 months (95% CI, 6.7- 10.0), the median time to progressive disease was 9.6 months (95% CI, 8.5- 11.0), and the median time to treatment failure was 9.3 months (95% CI, 8.2- 10.4). The main grade 3/4 toxicities were neutropenia (78% of patients), leukopenia (30% ), thrombocytopenia (18% ), and anemia (15% ); no grade 4 nonhematologic toxicities occurred, and grade 3 nonhematologic toxicities were mild. The combination of gemcitabine and carboplatin is active and feasible in platinum- sensitive patients with recurrent ovarian cancer. This regimen is undergoing further evaluation in a large phase III trial.
